Introduction: the hunger hormone with a second job

Ghrelin is best known as the "hunger hormone" — circulating levels rise before meals, generating appetite, and fall post-prandially in healthy individuals. This orexigenic identity obscures a richer biology: ghrelin and its receptor, GHSR-1a, are also the primary peripheral signal to the pituitary for growth hormone secretagogue activity, modulate energy homeostasis, influence sleep architecture, and play roles in memory consolidation and stress response. For researchers investigating metabolic peptides, the GHSR pathway is principally relevant as a mechanism for amplifying physiological GH pulsatility — with ipamorelin representing the cleanest available pharmacological probe of that pathway in a research context.

Ghrelin: structure and endogenous physiology

Ghrelin is a 28-amino-acid peptide requiring octanoylation (an eight-carbon fatty-acid acyl modification) at Ser3 for full GHSR-1a agonism. This acylation — catalysed by the enzyme ghrelin O-acyltransferase (GOAT) — makes ghrelin unique among peptide hormones as the only known endogenous compound requiring a post-translational lipid modification for activity at its primary receptor. Unacylated ghrelin (des-acyl ghrelin) is present at higher circulating concentrations than acylated ghrelin but does not substantially activate GHSR-1a; it may exert separate physiological effects through as-yet incompletely characterised receptors.

Ghrelin is produced primarily by X/A-like cells in the oxyntic mucosa of the gastric fundus, with lower-level production in the hypothalamus, pituitary, adrenal gland, and small intestine. Circulating levels follow a diurnal pattern inverse to that of leptin: peak levels occur in the late morning and late evening, coinciding with pre-meal hunger; the nocturnal ghrelin surge during early sleep is one of several signals driving the dominant sleep-associated GH pulse.

GHSR-1a: receptor pharmacology and neural distribution

The growth hormone secretagogue receptor (GHSR) gene encodes two splice variants: GHSR-1a (the full-length, constitutively active receptor) and GHSR-1b (a truncated variant without signalling capacity, believed to act as a negative regulator by sequestering GHSR-1a). Therapeutic and research interest focuses entirely on GHSR-1a.

GHSR-1a is notable for its unusually high constitutive activity — approximately 50% of maximal receptor activity occurs in the absence of any ligand, a property that confers basal tone on the GH axis independent of circulating ghrelin and has implications for the pharmacological interpretation of "selective" compounds that may act as inverse agonists rather than neutral antagonists. GHSR-1a couples primarily to Gαq, activating phospholipase C-β (PLCβ), which hydrolyses phosphatidylinositol 4,5-bisphosphate (PIP₂) to generate inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 mobilises intracellular calcium from the endoplasmic reticulum; DAG activates protein kinase C (PKC). The resulting calcium transient triggers GH-containing vesicle exocytosis in somatotropes.

Hypothalamic distribution: GHSR-1a expression in the arcuate nucleus is concentrated on AgRP/NPY neurons — the primary appetite-stimulating population. GHSR-1a activation depolarises these neurons, releasing neuropeptide Y (NPY) and agouti-related protein (AgRP) into the paraventricular nucleus, promoting hunger. This hypothalamic appetite circuit is mechanistically distinct from the pituitary somatotrope pathway and represents an unavoidable on-target effect of GHSR-1a agonism that must be considered in timing and dosing strategies.

GHSR-1a is also expressed in hippocampal CA1/CA3 neurons (memory consolidation), the dorsal vagal complex (energy-intake regulation via vagal afferents), and adrenal cortex (where stimulation can elevate cortisol — notably, a pathway exploited by non-selective GHS compounds but avoided by ipamorelin).

Ipamorelin: engineering selectivity into a ghrelin mimetic

Ipamorelin (Ala-His-D-2-Nal-D-Phe-Lys-NH₂) is a pentapeptide growth hormone secretagogue developed by Novo Nordisk in the late 1990s and subsequently advanced as a research compound. It was designed through iterative structure-activity relationship (SAR) studies starting from GHRP-2 and GHRP-6, with the goal of identifying the minimal pharmacophore required for high-affinity GHSR-1a agonism while eliminating the off-target effects (cortisol, prolactin) that characterised earlier growth hormone secretagogue peptides.

Selectivity profile: In preclinical and Phase 1 studies, ipamorelin at doses producing maximal GH release demonstrated no statistically significant elevation in:

Cortisol/ACTH: GHRP-6 and hexarelin stimulate cortisol release via GHSR-1a on adrenal cortex and through central CRH pathways; ipamorelin does not — a consequence of its structural inability to effectively activate the GHSR-1a conformation linked to adrenal signalling versus the somatotrope-specific conformation.
Prolactin: Unlike GHRP-6, ipamorelin does not stimulate lactotrope prolactin release, avoiding a side effect that can disrupt reproductive hormone profiles.
FSH/LH: Gonadotrophin axes are unaffected at research doses.

This selectivity makes ipamorelin a pharmacologically clean probe of GHSR-1a-mediated somatotrope stimulation in research contexts — the GH response can be attributed specifically to GHSR-1a activation rather than to adrenal or lactotrope co-stimulation.

GHSR/GHRHR synergy: why the combination is greater than the sum

The combination of a GHRH analogue (CJC-1295 or tesamorelin) with ipamorelin has emerged as the most studied dual-pathway GH optimisation strategy in research protocols. The mechanistic rationale is rooted in signal-cascade complementarity:

GHRHR (Gαs/cAMP/PKA): Raises somatotrope cAMP, upregulates GH gene transcription, and primes the exocytosis machinery through CREB-mediated gene expression over 30–60 minutes.
GHSR-1a (Gαq/PLC/Ca²⁺): Provides the immediate calcium transient that triggers vesicle fusion and GH exocytosis within seconds to minutes.

The cAMP priming (GHRHR) and calcium-triggered firing (GHSR) represent sequential, mechanistically independent events in the GH secretion cascade. Co-administration exploits both simultaneously: the GHRHR signal primes a larger cohort of secretory vesicles; the GHSR calcium signal fires them all at once. Preclinical studies demonstrated that GHRH + ghrelin or ghrelin mimetic co-administration produces GH peaks 4–10× greater than either agent alone — a genuine pharmacodynamic synergy rather than simple additive effect.

In clinical research applications, the CJC-1295/ipamorelin combination is typically administered via subcutaneous injection, with timing protocols designed to coincide the GH pulse with the natural nocturnal window to preserve circadian GH rhythm.

Appetite circuit considerations

Because GHSR-1a activation in arcuate AgRP/NPY neurons promotes hunger, GHSR agonism carries a transient orexigenic effect. In healthy individuals with intact GLP-1 and leptin signalling, this effect is usually brief and self-limiting. However, when ipamorelin is used alongside GLP-1R agonists (which suppress appetite via overlapping hypothalamic circuits), the opposing signals may partially counteract each other. This mechanistic tension is relevant when designing combination protocols and highlights the importance of understanding the receptor-level distribution of competing hypothalamic signals.

Trial data: Phase 2 evidence for ipamorelin

Ipamorelin has been evaluated in two completed Phase 2 trials. In a randomised, placebo-controlled trial in postoperative ileus (NovaBay/Novo Nordisk NNC 26-0161, 2009), ipamorelin demonstrated accelerated gastrointestinal recovery — an effect mediated in part through peripheral GHSR-1a on enteric neurons and smooth muscle rather than central GH secretion. This underscores the breadth of GHSR-1a tissue expression. A second programme in frail older adults demonstrated that ipamorelin increased GH pulse amplitude and 24-hour mean GH concentrations without elevating cortisol or causing tachyphylaxis over 12 weeks — directly supporting the selectivity and sustained efficacy claims from preclinical studies.

Why this matters for next-generation compounds

Understanding GHSR biology is increasingly relevant as the field explores combination approaches targeting both the caloric-restriction axis (GLP-1R/GIPR) and the body-composition axis (GHRH/GHSR). Theoretical combination frameworks propose that GLP-1R/GIPR agonism drives the caloric deficit while GHRH/GHSR co-agonism preserves or builds lean mass, shifting the weight-loss composition towards fat rather than a 25–40% lean-mass component. Early clinical investigations of peptide combinations are under way, and the selective pharmacological profile of ipamorelin makes it the preferred GHSR research probe in this context — avoiding the cortisol elevation that would confound metabolic outcome measurements in combination protocols.

GHSR and ghrelin receptor mechanism